Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green Sells 918 Shares

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 918 shares of the company’s stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $40.91, for a total value of $37,555.38. Following the completion of the transaction, the senior vice president now directly owns 130,912 shares in the company, valued at approximately $5,355,609.92. The trade was a 0.70 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Paula Green also recently made the following trade(s):

• On Monday, February 3rd, Paula Green sold 1,259 shares of Twist Bioscience stock. The shares were sold at an average price of $49.35, for a total value of $62,131.65.
• On Friday, January 3rd, Paula Green sold 160 shares of Twist Bioscience stock. The stock was sold at an average price of $45.59, for a total value of $7,294.40.
• On Friday, December 20th, Paula Green sold 282 shares of Twist Bioscience stock. The shares were sold at an average price of $44.90, for a total transaction of $12,661.80.

Twist Bioscience Stock Performance

TWST opened at $39.32 on Thursday. The company has a market cap of $2.35 billion, a PE ratio of -11.63 and a beta of 2.15. The stock has a 50-day moving average of $46.18 and a 200-day moving average of $45.39. Twist Bioscience Co. has a 52-week low of $27.41 and a 52-week high of $60.90. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.09. The company had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The firm’s revenue was up 24.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.75) EPS. As a group, equities research analysts forecast that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Institutional Trading of Twist Bioscience

Several large investors have recently made changes to their positions in the stock. Arizona State Retirement System boosted its stake in shares of Twist Bioscience by 1.3% during the 4th quarter. Arizona State Retirement System now owns 16,985 shares of the company’s stock worth $789,000 after acquiring an additional 219 shares in the last quarter. Van ECK Associates Corp boosted its stake in Twist Bioscience by 56.4% during the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock valued at $34,000 after purchasing an additional 267 shares during the period. Hillsdale Investment Management Inc. boosted its stake in Twist Bioscience by 0.4% during the 4th quarter. Hillsdale Investment Management Inc. now owns 78,000 shares of the company’s stock valued at $3,625,000 after purchasing an additional 300 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Twist Bioscience by 2.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,243 shares of the company’s stock valued at $734,000 after purchasing an additional 363 shares during the period. Finally, Deerfield Management Company L.P. Series C boosted its stake in Twist Bioscience by 1.7% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 23,827 shares of the company’s stock valued at $1,107,000 after purchasing an additional 403 shares during the period.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on TWST shares. Robert W. Baird lifted their price objective on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research note on Tuesday, February 4th. Scotiabank reiterated an “outperform” rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. Barclays set a $58.00 target price on shares of Twist Bioscience and gave the stock an “overweight” rating in a report on Monday, February 3rd. Wolfe Research started coverage on Twist Bioscience in a report on Friday, December 13th. They set an “outperform” rating and a $60.00 price target on the stock. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a research report on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $54.40.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.